Eledon Pharmaceuticals Stock Performance
| ELDN Stock | USD 2.41 0.11 4.78% |
On a scale of 0 to 100, Eledon Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of 0.83, which means possible diversification benefits within a given portfolio. As returns on the market increase, Eledon Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Eledon Pharmaceuticals is expected to be smaller as well. Please check Eledon Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Eledon Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Eledon Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak fundamental indicators, Eledon Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 4.78 | Five Day Return 16.43 | Year To Date Return 28.19 | Ten Year Return (99.94) | All Time Return (99.94) |
Last Split Factor 1:18 | Dividend Date 2020-10-05 | Last Split Date 2020-10-05 |
1 | Eledon Pharmaceuticals, Inc. Expected to Post Q1 2024 Earnings of Per Share - Defense World | 02/09/2024 |
2 | Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 02/14/2024 |
3 | Comparing Eledon Pharmaceuticals Pharmaxis - Defense World | 03/14/2024 |
4 | Disposition of 12942 shares by Logos Global Management Lp of Eledon Pharmaceuticals at 26.6442 subject to Rule 16b-3 | 04/08/2024 |
5 | Disposition of 10415 shares by Ogier Walter C of Eledon Pharmaceuticals at 0.6855 subject to Rule 16b-3 | 04/26/2024 |
6 | Discretionary transaction by Logos Global Management Lp of tradable shares of Eledon Pharmaceuticals subject to Rule 16b-3 | 05/02/2024 |
| Begin Period Cash Flow | 56.4 M |
Eledon |
Eledon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 175.00 in Eledon Pharmaceuticals on February 5, 2024 and sell it today you would earn a total of 66.00 from holding Eledon Pharmaceuticals or generate 37.71% return on investment over 90 days. Eledon Pharmaceuticals is currently generating 0.6532% in daily expected returns and assumes 5.702% risk (volatility on return distribution) over the 90 days horizon. In different words, 50% of stocks are less volatile than Eledon, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eledon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eledon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eledon Pharmaceuticals, and traders can use it to determine the average amount a Eledon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1145
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ELDN | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.7 actual daily | 50 50% of assets are less volatile |
Expected Return
| 0.65 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Eledon Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eledon Pharmaceuticals by adding it to a well-diversified portfolio.
Eledon Pharmaceuticals Fundamentals Growth
Eledon Stock prices reflect investors' perceptions of the future prospects and financial health of Eledon Pharmaceuticals, and Eledon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eledon Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | 9.08 M | ||||
| Shares Outstanding | 24.81 M | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | (42.63 M) | ||||
| Net Income | (40.33 M) | ||||
| Cash And Equivalents | 70.46 M | ||||
| Cash Per Share | 5.12 X | ||||
| Total Debt | 383 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 22.22 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (39.53 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 59.8 M | ||||
| Total Asset | 125.89 M | ||||
| Retained Earnings | (243.19 M) | ||||
| Working Capital | 52.23 M | ||||
About Eledon Pharmaceuticals Performance
To evaluate Eledon Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Eledon Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Eledon Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Eledon Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Eledon's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.3 K | 1.7 K | |
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.48) | (0.51) |
Things to note about Eledon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eledon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eledon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eledon Pharmaceuticals is way too risky over 90 days horizon | |
| Eledon Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Eledon Pharmaceuticals currently holds about 70.46 M in cash with (39.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Discretionary transaction by Logos Global Management Lp of tradable shares of Eledon Pharmaceuticals subject to Rule 16b-3 |
- Analyzing Eledon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eledon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eledon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eledon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eledon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eledon Pharmaceuticals' stock. These opinions can provide insight into Eledon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Note that the Eledon Pharmaceuticals information on this page should be used as a complementary analysis to other Eledon Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Eledon Stock analysis
When running Eledon Pharmaceuticals' price analysis, check to measure Eledon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eledon Pharmaceuticals is operating at the current time. Most of Eledon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eledon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eledon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eledon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Eledon Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Return On Assets (0.30) | Return On Equity (0.48) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.